• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Blockbuster Drugs Rituxan, Avastin, and Erbitux Changes the Way the Pharmaceutical Industry Looks Upon Antibody Treatment Of Cancer

Posted on: Monday, 5 December 2005, 09:01 CST

Research and Markets (http://www.researchandmarkets.com/reports/c28867) has announced the addition of The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave to their offering.

The blockbuster drugs Rituxan, Avastin, and Erbitux have changed the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics.

Scope of this report

Thorough examination of the top eight cancer therapeutic antibodies on the market.

The race towards the next generation of therapeutic antibodies and improved drug delivery methods there of.

Antibody deals are on the rise, where of those targeting oncology is the single most active area.

Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.

Research and analysis highlights

The commercial and therapeutic success of antibodies will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies. The first-generation formulations of therapeutic antibodies will be facing heavy competition from biogeneric companies as their profitable antibody drugs comes off patent in the future. Among the different strategies (e.g., antibody engineering, changes in primary structure, fusions, chemical modifications glycosylation, pegylation, polymer conjugates), the approach of miniaturizing and delivering antibody drugs is the most promising because it permits better release of active drugs.

Key reasons to read this report

One source to the top cancer therapeutic antibodies on the market.

Key insights into the second wave in the lucrative field of therapeutic antibodies.

Competitive landscape assessment, including deals, technologies and more than 100 companies in the field and close to 100 cancer therapeutic antibodies.

The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second

Wave

-- Executive Summary

-- Cancer Highlights

-- Methodology

-- Key Developmental Strategies

-- Treating Colorectal Cancer

-- Treating Lymphomas

-- Treating Leukemias

-- Treating Lung cancer

-- Antibody Deals on the Rise

-- New Approaches in Antibody Delivery and Design - The Next Generation

-- Current Analysis of Mabs in Clinical Development

-- Appendix I: Cancer Therapeutic Antibodies in Clinical Development

-- Appendix II: Discontinued Projects - A Five Year Recapitulation

-- Appendix III: Selected Company Profiles

-- Disclaimer

-- Drug Index

-- Company Index

-- List of Boxes

-- List of Tables

For more information visit http://www.researchandmarkets.com/reports/c28867

Source: Business Wire

More News in this Category